Loading data…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$57M net income for the year ended October 31, 2025. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| November 1, 2024 – October 31, 2025 | $34,296,000,000 | December 18, 2025 | 10-K ↗ |
| November 1, 2023 – October 31, 2024 | $30,127,000,000 | December 18, 2025 | 10-K ↗ |
| November 1, 2022 – October 31, 2023 | $29,135,000,000 | December 18, 2025 | 10-K ↗ |
| November 1, 2021 – October 31, 2022 | $28,496,000,000 | December 19, 2024 | 10-K ↗ |
| November 1, 2020 – October 31, 2021 | $27,784,000,000 | December 22, 2023 | 10-K ↗ |
| November 1, 2019 – October 31, 2020 | $26,982,000,000 | December 8, 2022 | 10-K ↗ |
| November 1, 2018 – October 31, 2019 | $29,135,000,000 | December 10, 2021 | 10-K ↗ |
| November 1, 2017 – October 31, 2018 | $30,852,000,000 | December 10, 2020 | 10-K ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:Revenues · Retrieved October 14, 2026
Response SHA-256: e2800dcac4b3530c289f7494e3fcf9be38378fba1ef9172483f50976ae0568d1
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.